Advertisement

Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Document › Details

Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen.

Organisations Organisation Immatics N.V. (Nasdaq: IMTX)
  Group Immatics (Group)
  Organisation 2 Trophic Communications GmbH
Products Product IMA203 TCR-T candidate targeting PRAME (ACTengine)
  Product 2 phase 1 study
Persons Person Britten, Cedrik (Immatics 202006– CMO before GSK VP + Head of Oncology Cell Therapy Research Unit + BioNTech)
  Person 2 Mulder, Eva (Trophic Commincations 202005– Account Director before Uniqure)
     


   
Record changed: 2023-06-05

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Immatics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top